Show simple item record

dc.contributor.authorAndrieux-Meyer, Isabelleen_GB
dc.contributor.authorCalmy, Alexandraen_GB
dc.contributor.authorCahn, Pedroen_GB
dc.contributor.authorClayden, Pollyen_GB
dc.contributor.authorRaguin, Gillesen_GB
dc.contributor.authorKatlama, Christineen_GB
dc.contributor.authorVitoria, Marcoen_GB
dc.contributor.authorLevin, Andrewen_GB
dc.contributor.authorLynch, Sharonannen_GB
dc.contributor.authorGoemaere, Ericen_GB
dc.contributor.authorFord, Nathanen_GB
dc.date.accessioned2013-04-11T22:15:50Z
dc.date.available2013-04-11T22:15:50Z
dc.date.issued2012-09-18
dc.identifier.citationPreferred antiretroviral drugs for the next decade of scale up. 2012, 15 (2):17986 J Int AIDS Socen_GB
dc.identifier.issn1758-2652
dc.identifier.pmid23010379
dc.identifier.urihttp://hdl.handle.net/10144/280933
dc.description.abstractGlobal commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer-term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings.
dc.language.isoenen
dc.rightsArchived with thanks to Journal of the International AIDS Societyen_GB
dc.subject.meshAnti-Retroviral Agentsen_GB
dc.subject.meshAntiretroviral Therapy, Highly Activeen_GB
dc.subject.meshGuidelines as Topicen_GB
dc.subject.meshHIV Infectionsen_GB
dc.subject.meshHumansen_GB
dc.titlePreferred antiretroviral drugs for the next decade of scale upen
dc.contributor.departmentMédecins Sans Frontières, Geneva, Switzerland.en_GB
dc.identifier.journalJournal of the International AIDS Societyen_GB
refterms.dateFOA2019-03-04T10:29:22Z
html.description.abstractGlobal commitments aim to provide antiretroviral therapy (ART) to 15 million people living with HIV by 2015, and recent studies have demonstrated the potential for widespread ART to prevent HIV transmission. Increasingly, countries are adapting their national guidelines to start ART earlier, for both clinical and preventive benefits. To maximize the benefits of ART in resource-limited settings, six key principles need to guide ART choice: simplicity, tolerability and safety, durability, universal applicability, affordability and heat stability. Currently available drugs, combined with those in late-stage clinical development, hold great promise to simplify treatment in the short term. Over the longer-term, newer technologies, such as long-acting formulations and nanotechnology, could radically alter the treatment paradigm. This commentary reviews recommendations made in an expert consultation on treatment scale up in resource-limited settings.


Files in this item

Thumbnail
Name:
Andrieux-Meyer - Preferred ...
Size:
175.7Kb
Format:
PDF

This item appears in the following Collection(s)

Show simple item record